Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:25:55.847Z.
Calculation as of: 2026-10-06T15:25:55.847Z.
Quote observation: 2026-10-06T15:25:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Aprea Therapeutics, Inc.
Market Cap
$8.14M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.14M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.30M | N/A |
| HeartSciences Inc. (HSCS)vs › | $7.90M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.90M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.86M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.97M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.53M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.43M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.28M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.24M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
